Seasonal variations of serum-IgE and potential impact on dose-calculation of omalizumab (rhuMab-E25, anti-IgE);Saisonale schwankungen des serum-IgE-spiegels und deren mögliche bedeutung für die berechnung der therapeutischen dosis von omalizumab (rhuMab-E25, anti-IgE)

Pneumologie

Volumn 58, Issue 8, 2004, Pages 546-551

  Beeh, K M ^a   Beier, J ^b   Buhl, R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Institut fur Atemwegsforschung INSAF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; DOSE CALCULATION; DRUG DOSE REGIMEN; GRASS POLLEN; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; PRIORITY JOURNAL; SEASONAL VARIATION; STATISTICAL SIGNIFICANCE;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 4344564324     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818483     Document Type: Article

References (19)

1. Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123: 196-204
2. Buhl R, Soler M, Matz J et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73-78
3. Busse WW, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190
4. Milgrom H, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341: 1966-1973
5. Adelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-259
6. Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280
7. Casale TB, Condemi JJ, LaForce C et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA 2001; 286: 2956-2967
8. Casale TB, Bernstein IL, Busse WW et al. Use of an anti-Ige humanized monoclonal antobody in ragweed-induced allergic rhinits. J Allergy Clin Immunol 1997; 100: 110-121
9. Malveaux FJ, Conroy MC, Adkinson Jr NF et al. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 1978; 62: 176-181
10. Xolair - package information leaflet. Australia, 2003
11. Masamoto T, Ohashi Y, Nakai Y. Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Ann Otol Rhinol Laryngol 2004; 108: 169-176
12. Rossi RE, Monasterolo G, Operti D et al. Evaluation of IgE antibodies to recombinant pollen allergens (PhI p 1, PhI p 2, and PhI p 5) in a random sample of patients with specific IgE to Phleum pratense. Allergy 2004; 55: 181-184
13. Bland JM, Altman DC. Transformations, means, and confidence intervals. Br Med J 1996; 312: 1079
14. Boulet LP, Turcotte H, Laprise C et al. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin Exp Allergy 1997; 27: 52-59
15. Corne J. Do inhaled corticosteroids reduce serum IgE levels? The answer is maybe but how relevant is the question? Clin Exp Allergy 1999; 29: 294-297
16. Wosinska-Becler K, Plewako H, Hakansson L et al. Cytokine production in peripheral blood cells during and out of the pollen season in birch-allergic patients and non-allergic controls. Clin Exp Allergy 2004; 34: 123-130
17. Takeoka K, Hidaka Y, Hanada H et al. Increase in serum levels of autoantibodies after attack of seasonal allergic rhinitis in patients with Graves' disease. Int Arch Allergy Immunol 2003; 132: 268-276
18. Ohashi Y, Nakai Y, Tanaka A et al. Seasonal rise in interleukin-4 during pollen season is related to seasonal rise in specific IgE for pollens but not for mites. Acta Otolaryngol 1998; 118: 243-247
19. MacGlashan DW, Bochner BS, Adelman DC et al. Down-regulation of FCeRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-1445